arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Tenaya Therapeutics, Inc.

TNYA
$0.32 ▼ -0.05 (-13.78%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tenaya Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $69.6M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -63.5% ↘
FCF / Share $-0.02 ↗
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.11M
↑ +393.3% —
Net Income Profit after all expenses
$-19.27M
↑ +28.3% —
FCF / Share Free cash flow per share
$-0.02
↑ +82.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Cash Quality ↓
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters